Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$16.1 million.

  • Solid Biosciences' Cash from Investing Activities fell 14.86% to $38.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$16.1 million, marking a year-over-year decrease of 266.02%. This contributed to the annual value of -$16.1 million for FY2024, which is 266.02% down from last year.
  • According to the latest figures from FY2024, Solid Biosciences' Cash from Investing Activities is -$16.1 million, which was down 266.02% from $9.7 million recorded in FY2023.
  • In the past 5 years, Solid Biosciences' Cash from Investing Activities registered a high of $59.2 million during FY2022, and its lowest value of -$91.1 million during FY2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $9.7 million (2023), whereas its average is $17.6 million.
  • In the last 5 years, Solid Biosciences' Cash from Investing Activities plummeted by 1,480.09% in 2021 and then skyrocketed by 164.95% in 2022.
  • Yearly analysis of 5 years shows Solid Biosciences' Cash from Investing Activities stood at $6.6 million in 2020, then tumbled by 1,480.09% to -$91.1 million in 2021, then skyrocketed by 164.95% to $59.2 million in 2022, then slumped by 83.62% to $9.7 million in 2023, then tumbled by 266.02% to -$16.1 million in 2024.